Alnylam Pharmaceuticals (ALNY) Interest & Investment Income (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 18 years of Interest & Investment Income data on file, last reported at $28.1 million in Q2 2026.

• Quarterly Interest & Investment Income rose 2.39% year-over-year to $28.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $110.1 million (down 7.77% YoY) and the FY2025 annual result came in at $111.5 million, down 8.63% from the prior year.
• Interest & Investment Income climbed to $28.1 million in Q2 2026, from $26.6 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $35.8 million in Q4 2022 to a low of -$7.2 million in Q1 2022.
• A 5-year average of $23.4 million and a median of $27.8 million in 2025 frame the typical range for Interest & Investment Income.
• The widest YoY moves for Interest & Investment Income: up 12318.75% in 2022, down 1703.78% in 2022.
• Tracing ALNY's Interest & Investment Income over 5 years: stood at $35.8 million in 2022, then declined by 15.1% to $30.4 million in 2023, then climbed by 2.02% to $31.0 million in 2024, then retreated by 14.15% to $26.6 million in 2025, then rose by 5.68% to $28.1 million in 2026.
• The last three Interest & Investment Income figures came in at $28.1 million (Q2 2026), $26.6 million (Q1 2026), and $26.6 million (Q4 2025), per Business Quant data.